BioNTech

BioNTech剥离德国根系：168亿欧元现金弹药与七项临床数据决定下半年走向

angelina -

BioNTech’s Balancing Act: A Founder Exodus Meets a Make-or-Break Oncology Pipeline

Brett Shapiro -

BioNTech的转折之战：十亿美元回购托底，肿瘤药FDA申请进入读秒

Brett Shapiro -

BioNTech Faces Twin Uncertainties: Who Will Lead and Who Will Own the Oncology Pipeline?

BioNTech六月末关键战役：分拆、收购与ADC临床数据三重共振

BioNTech Enters a Second Half Defined by Seven Readouts and a Leadership Puzzle

angelina -

BioNTech的79.85欧元困局：管理真空与临床密集期叠加，市场在等什么？

angelina -

BioNTech Targets First Oncology Approval in 2026 While Spinning Off mRNA Legacy

angelina -

BioNTech转型暗礁：分拆倒计时与临床试验诉讼双重夹击

kashif hafeez -

BioNTech Builds in Australia Even as It Cuts Jobs and Sheds Factories

BioNTech的六月大考：分拆截止日逼近，Moderna接盘工厂添变数

kashif hafeez -

BioNTech双重博弈：技术面深陷泥潭，6+7项临床数据待破局

kashif hafeez -

BioNTech转型十字路口：百亿现金押注肿瘤赛道，市场为何仍在观望？

BioNTech里程碑时刻：首个肿瘤药FDA申请在即，15项三期临床蓄势待发

angelina -

BioNTech’s First US Cancer Filing Arrives With a Leadership Vacuum and a Pipeline That Investors Can’t Ignore

kashif hafeez -
1234...12Page 3 of 12